Tusq Dx

# TusQ dx ## Overview - **Classification**: Combination cough and cold medication (antitussive, decongestant, antihistamine). - **Mechanism**: Dextromethorphan suppresses the cough reflex in the medulla. Phenylephrine is an alpha-adrenergic agonist, causing vasoconstriction to reduce nasal congestion. Chlorpheniramine is a first-generation H1-antihistamine, reducing histamine effects like sneezing and rhinorrhea. ## Primary Indications 1. **Cough Suppression** - Relief of non-productive cough associated with colds or allergies. 2. **Nasal Congestion** - Reduction of stuffy nose and sinus pressure. 3. **Allergy Symptoms** - Alleviation of sneezing, watery eyes, and runny nose. ## Adult Dosing ### Standard Dosing **Common Cold/Allergy Symptoms** - **Dose**: **10 mL** oral solution (typically containing **Dextromethorphan 15 mg, Phenylephrine 5 mg, Chlorpheniramine 2 mg**). - **Frequency**: Every **4-6 hours** as needed. - **Route**: Oral. - **Maximum Dose**: Do not exceed **40 mL** in 24 hours (**60 mg Dextromethorphan, 20 mg Phenylephrine, 8 mg Chlorpheniramine**). ### Dose Adjustments - **Renal Impairment**: Use with caution. Consider reduced frequency or lower dose if CrCl < **30 mL/min** due to potential accumulation of renally excreted components. - **Hepatic Impairment**: Use with caution. Consider lower doses if severe hepatic dysfunction, as components are hepatically metabolized. - **Elderly Patients**: Use with caution due to increased sensitivity to anticholinergic (Chlorpheniramine) and adrenergic (Phenylephrine) effects. Start with lower doses; avoid in patients with BPH, glaucoma, or uncontrolled hypertension. ## Pediatric Dosing **⚠️ IMPORTANT SAFETY WARNING ⚠️** * **Not recommended for children under 4 years of age.** Serious adverse events including respiratory depression, cardiac events, and death have been reported. * Consult a pediatrician before use in children **4 to 6 years of age**; benefits rarely outweigh risks. ### Neonates (0-28 days) - **Not recommended.** Contraindicated due to serious safety risks (respiratory depression, CNS effects, cardiovascular effects) associated with all active components. ### Infants (1-12 months) - **Not recommended.** Contraindicated due to serious safety risks (respiratory depression, CNS effects, cardiovascular effects). ### Children (1-12 years) - **Children 1-3 years**: **Not recommended.** See general safety warning above. - **Children 4-6 years**: Use with extreme caution, only if advised by a healthcare professional. - **Dose**: Typically **2.5-5 mL** oral solution. - **Frequency**: Every **4-6 hours** as needed. - **Maximum**: **3-4 doses** in 24 hours, not to exceed product-specific daily limits. - **Children 6-12 years**: - **Dose**: **5 mL** oral solution (half of adult dose). - **Frequency**: Every **4-6 hours** as needed. - **Maximum**: Do not exceed **20 mL** in 24 hours (**30 mg Dextromethorphan, 10 mg Phenylephrine, 4 mg Chlorpheniramine**). - **Special Notes**: Always use an accurate measuring device. Monitor closely for sedation and cardiovascular effects. ### Adolescents (13-18 years) - **Dose**: Follow adult dosing guidelines, typically **10 mL** oral solution. - **Frequency**: Every **4-6 hours** as needed. - **Maximum**: Do not exceed **40 mL** in 24 hours. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to any component or excipients. - **Absolute**: Concurrent use with or within **14 days** of MAO inhibitors (MAOIs) due to risk of hypertensive crisis and serotonin syndrome. - **Absolute**: Severe hypertension, severe coronary artery disease. - **Absolute**: Narrow-angle glaucoma, urinary retention (due to anticholinergic effects). - **Absolute**: Children **under 4 years** of age. ### Common Adverse Effects - **Very Common (>10%)**: Drowsiness, dizziness, sedation (especially from Chlorpheniramine). - **Common (1-10%)**: Nausea, vomiting, dry mouth, blurred vision, nervousness, insomnia, headache. - **Serious but Rare**: Seizures, cardiac arrhythmias, severe hypertension, hallucinations, serotonin syndrome (with other serotonergic drugs). ### Key Drug Interactions - **MAO Inhibitors (MAOIs)**: **Absolute contraindication**. Leads to severe hypertensive crisis and/or serotonin syndrome. - **SSRIs/SNRIs/TCAs**: Increased risk of serotonin syndrome with Dextromethorphan. Monitor for changes in mental status, autonomic instability. - **Other CNS Depressants (Alcohol, Sedatives, Opioids)**: Enhanced sedation and respiratory depression. Avoid concomitant use. - **Beta-Blockers**: Phenylephrine may reduce antihypertensive effect; increased risk of hypertension. - **Anticholinergics (e.g., tricyclic antidepressants)**: Enhanced anticholinergic effects (dry mouth, urinary retention, blurred vision). ## Monitoring & Follow-up - **Before Treatment**: Assess for contraindications, especially MAOI use, severe cardiovascular disease, and glaucoma. - **During Treatment**: Monitor for CNS effects (drowsiness, agitation), cardiovascular effects (tachycardia, blood pressure changes), and urinary retention. - **Clinical Signs**: Watch for worsening symptoms, rash, or difficulty breathing; seek immediate medical attention for severe reactions. ## Clinical Pearls - 💡 **OTC Product**: TusQ dx is available over-the-counter; counsel patients on appropriate use, dosing, and potential risks. - 💡 **Hydration**: Encourage adequate fluid intake to help thin respiratory secretions and soothe the throat. - 💡 **Sedation Risk**: Advise patients about potential drowsiness; caution against driving or operating heavy machinery until effects are known. - 💡 **Accurate Dosing**: Always use a calibrated measuring device (oral syringe or cup) for liquid formulations, especially in children, to prevent overdosing. - 💡 **Abuse Potential**: Dextromethorphan has abuse potential. Counsel patients on using only as directed. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.